MedTrace Logo

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

NCT02613026 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-11-24

No results posted yet for this study

Summary

The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Pirarubicin

DRUG

Docetaxel

DRUG

Cyclophosphamide

Sponsors & Collaborators

  • 307 Hospital of PLA

    lead OTHER

Principal Investigators

  • Shikai Wu · 307 Hospital of PLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-03-31
Completion
2015-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02613026 on ClinicalTrials.gov